The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lupus content recommended for you
Laurent ArnaudDuring the 38th Annual Conference of Indian Rheumatology Association (IRACON) 2023, the Lupus Hub was pleased to speak with Laurent Arnaud, Strasbourg University School of Medicine, Strasbourg, FR. We asked about the current challenges in the management of systemic lupus erythematosus (SLE).
Current challenges in the management of systemic lupus erythematosus
Arnaud begins by addressing damage accrual in patients with SLE resulting from uncontrolled disease activity and treatment side effects, particularly due to corticosteroids. He explores the concept of treat-to-target and disease modification, emphasizing the need for early intervention. Arnaud emphasizes achieving the definition of remission in SLE (DORIS) and having a plan B for attaining Lupus Low Disease Activity State (LLDAS). Acknowledging substantial drug trial failures, he mentions 92 drugs currently under development, with more than 15 in phase II, and expresses hope for their success. While more data are warranted to support the early use of biologics, he advises optimizing existing treatments with hydroxychloroquine, immunosuppressants, and prudent corticosteroid use.